HIGHLIGHT

Protein kinase A in Carney complex: a new example of cAMP pathway alteration in endocrine tumors

Jérôme Bertherat

Service d’endocrinologie and CNRS UPR 1524, CHU Cochin, 27 rue du Fg-St-Jacques, 75014, Paris, France

(Correspondence should be addressed to J Bertherat; E-mail: jerome.bertherat@cch.ap-hop-paris.fr)

Cyclic AMP (cAMP) plays an important role in cellular differentiation and has a complex action on cellular proliferation. Activation of the cAMP pathway inhibits cellular proliferation in numerous tissues, but it can also stimulate cellular proliferation in a subset of endocrine cells. For instance, cAMP increases somatotroph and thyroid cells proliferation (1). In these tissues, cAMP is also the well known intracellular mediator of peptidic hormones (growth hormone releasing hormone (GHRH) and thyroid stimulating hormone (TSH) respectively) which play a major role in development and differentiation. These hormones bind to seven transmembranes receptors coupled to G stimulatory (Gs) protein. Inactivating mutation of several receptors coupled to Gs, such as the GHRH, adrenocorticotropin (ACTH) or TSH receptors, lead to hormone resistance and somatotroph, adrenal or thyroid deficiency respectively. Normal function of the cAMP pathway from the cell surface to the nucleus seems to be required for normal development of both the thyroid and the somatotrophs. Expression of a dominant negative mutant of the cAMP response element binding protein (CREB) non-phosphorylatable by protein kinase A (PKA) causes hypoplasia of the targeted organ and thyroid or somatotroph deficiency in transgenic mice (2).

Several diseases with endocrine gland hyperplasia or tumor, and hormone hypersecretion, can be secondary to activation of the extracellular signal that stimulates the cAMP pathway in a given tissue. Eutopic or ectopic GHRH or ACTH hypersecretion cause acromegaly with somatotroph hyperplasia or Cushing’s syndrome with adrenal bilateral hyperplasia. Pituitary tumors secreting TSH lead to the development of goiter and hyperthyroidism. Several molecular alterations mimicking overstimulation of the cAMP pathway by extracellular stimuli have been observed in various endocrine tumors. Somatic activating mutations of the TSH receptor causing ligand independent activation of cAMP production by adenyl cyclase are observed in most thyroid toxic adenomas (3). In these tumors, activation of the cAMP pathway could be linked to both thyroid hormone hypersecretion and cellular proliferation leading to adenoma development. Germ line inheritance of similar activating TSH receptor mutations have been observed in the dominant autosomic form of toxic nodular goiter. In the adrenal cortex, ectopic expression of the gastric inhibitory peptide receptor, also coupled to Gs, is associated with ACTH-independent macronodular adrenal hyperplasia or adenoma and food-dependent cortisol hypersecretion (4). Alterations of the Gs protein itself were reported more than 10 years ago in GH-secreting and thyroid tumors. These somatic activating Gs mutations (oncogene Gsp) lead to constitutive cAMP production (5). Similar mutations have also been reported in the McCune–Albright syndrome, presenting with ‘café au lait’ spot, bone fibrous dysplasia and various endocrine tumors: growth hormone (GH)-secreting adenomas, precocious puberty with ovarian cyst, toxic thyroid goiter, Cushing’s syndrome with ACTH-independent macronodular adrenal hyperplasia. Patients suffering from the McCune–Albright syndrome present with a mosaic distribution of the Gsp mutation (6).

Carney complex (CC) is an autosomic dominant disorder initially described as the association of myxomas, spotty skin pigmentation and endocrine overactivity and considered as a multiple neoplasia and lentiginosis syndrome. Various endocrine tumors are associated with the CC: GH-secreting adenomas, thyroid toxic adenomas, Sertoli cell testicular tumors, primary pigmented nodular adrenal hyperplasia with ACTH-independent Cushing’s syndrome. Cardiac myxomas and psammomatous melanotic schwannomas are among other various tumors observed in the CC (7). The CC share some features of the McCune–Albright syndrome. Because of these similarities genes controlling the cAMP pathway have been considered as candidates for CC. Mutation of Gs protein has not been found in CC. Two loci have been identified by linkage analysis in CC families. By this approach the putative genes responsible for CC have been mapped to chromosome 2p16 and 17q22-24. Genomic amplification of the 2p16 region in tumors from CC patients suggest that an oncogene is located at this locus. On the other hand loss of heterozygosity (LOH) of the 17q22-24 region in tumors from CC patients suggest that a tumor suppressor gene is located at this other locus. Study of LOH in CC tumors allowed C Stratakis and his team to redefine a 8-cM region at the 17q22-24 locus that retains the allele segregating with the disease. Among the known genes located in this region is the one encoding the regulatory subunit 1A of the cAMP dependent protein kinase (PKAR1A). Two

© 2001 Society of the European Journal of Endocrinology
Therefore, the ratio of R1A/R2B is altered and these level without compensatory R2B overexpression (9).

Tumors by Western blot analysis showed a reduced R1A of the PKA regulatory subunits R1A and R2B in CC inactivation of this regulatory subunit by the CC PKAR1A normally inhibits PKA activity, therefore also change during development or the cell cycle. And might be different among the tissues, but could various components of the PKA holoenzyme is complex factor phosphorylation. The equilibrium between the two catalytic subunits dissociate and become active. The After cAMP binding to the regulatory subunit, the regulatory subunit have been identified: R1A, R1B, R2A, R2B. The holoenzyme is the inactive tetramer. PKA is a tetramer consisting of two regulatory and two catalytic subunits. Four genes encoding the regulatory subunit have been identified: R1A, R1B, R2A, R2B. The holoenzyme is the inactive tetramer. After cAMP binding to the regulatory subunit, the catalytic subunits dissociate and become active. The free catalytic subunit therefore phosphorylates serine and threonine residues and is also able to enter the cell nucleus to regulate gene expression by transcription factor phosphorylation. The equilibrium between the various components of the PKA holoenzyme is complex and might be different among the tissues, but could also change during development or the cell cycle. PKAR1A normally inhibits PKA activity, therefore inactivation of this regulatory subunit by the CC mutation is expected to increase PKA activity if no compensatory mechanisms occur. Interestingly, study of the PKA regulatory subunits R1A and R2B in CC tumors by Western blot analysis showed a reduced R1A level without compensatory R2B overexpression (9). Therefore, the ratio of R1A/R2B is altered and these observations suggest that CC mutations lead to haploinsufficiency of PKAR1A. Study of PKA activity in CC tumors showed no change in basal activity compared with sporadic tumors from patients not affected by CC, but an increased PKA activity in response to cAMP was observed in CC tumors (8). An increased PKA activity in endocrine tumors of the CC is consistent with other molecular defects leading to cAMP pathway activation in sporadic GH-secreting or thyroid adenomas (both are endocrine tissues in which cAMP stimulates cell proliferation). Whether inactivating mutations of PKAR1A might have opposite effects in tissues where cAMP inhibits cellular proliferation is an interesting hypothesis that might be supported by a fine tissue specific regulation of the various regulatory subunits gene expression. Since PKA also stimulates tyrosine hydroxylase gene expression through phosphorylation of the transcription factor CREB, it might be interesting to speculate that increased skin pigmentation observed in CC might be explained by increased cutaneous PKA activity leading to stimulation of melanin biosynthesis.

So far the various molecular defects affecting the cAMP pathway reported in endocrine tumors altered gene encoding proteins located at the cell membrane level (i.e. receptors and G protein, Fig. 1). The report of PKAR1A mutations is the first example of a downstream defect in this pathway. Since the identification of the second CC susceptibility gene located on the 2p16 level (i.e. receptors and G protein, Fig. 1). The report of PKAR1A mutations is the first example of a downstream defect in this pathway. Since the identification of the second CC susceptibility gene located on the 2p16 form of Cushing's syndrome associated with adrenal hyperplasia, adrenal tumors, macro- or micro-nodular adenocortical hyperplasia. 1. Eutopic (Cushing's disease) or ectopic ACTH secretion. 2. Abnormal expression of membrane receptor: GIP (gastric-inhibitory peptide) receptor, β-adrenergic receptor (β), luteinizing hormone receptor (LH). 3. Activating mutation of the Gs subunit of the Gs protein, termed oncogene Gsp in McCune-Albright syndrome. 4. Inactivating mutation of the PKAR1A in Carney complex. AC, adenylyl cyclase; C, catalytic, R, regulatory subunit.

References

1 Bertherat J. Nuclear effects of the cAMP pathway activation in Cushing's syndrome. The figure shows alterations of the cAMP pathway at the extracellular (1), as well as the intracellular (2, 3, 4) level in various forms of Cushing's syndrome associated with adrenal hyperplasia, adrenal tumors, macro- or micro-nodular adenocortical hyperplasia. 1. Eutopic (Cushing's disease) or ectopic ACTH secretion. 2. Abnormal expression of membrane receptor: GIP (gastric-inhibitory peptide) receptor, β-adrenergic receptor (β), luteinizing hormone receptor (LH). 3. Activating mutation of the Gs subunit of the Gs protein, termed oncogene Gsp in McCune-Albright syndrome. 4. Inactivating mutation of the PKAR1A in Carney complex. AC, adenylyl cyclase; C, catalytic, R, regulatory subunit.

3 Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J & Vassart G. Somatic mutations in the thyrotropin

3 Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J & Vassart G. Somatic mutations in the thyrotropin


Received 24 November 2000
Accepted 27 November 2000